<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178839</url>
  </required_header>
  <id_info>
    <org_study_id>umsu.rec.1393.48</org_study_id>
    <nct_id>NCT02178839</nct_id>
  </id_info>
  <brief_title>The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease</brief_title>
  <official_title>The Effect of Oral β- Glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver Echogenicity and Enzymes in Non Alcoholic Fatty Liver Disease Treating With Hypocaloric Diet and Vitamin E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urmia University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urmia University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on
      Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in
      Non Alcoholic Fatty Liver Patients Treating with Hypocaloric Diet and Vitamin E.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver Echogenicity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Liver Echogenicity Describes by Grade,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Enzymes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Enzymes ALP (Alkanin Phosphatase), ALT (Alanin Amino Transferase) and AST (Aspartat Amino Transferase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurement WHtR</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>WHtR (waist to Height ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>NAS (numeric Analuge Scale) cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>8 weeeks</time_frame>
    <description>Describe by HOMA-IR (Homeostasis Model Assessment of Insulin Resistance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurement WC</measure>
    <time_frame>4weeks, 8 weeks</time_frame>
    <description>WC (waist circumference) measures by &quot;cm&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurement WHR</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>WHR (waist to hip ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurement BMI</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
    <description>BMI (Body Mass Index) kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY (PYY) Hormone</measure>
    <time_frame>8 weeks</time_frame>
    <description>Elayza kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholecystokinin (CKK) Hormone</measure>
    <time_frame>8 weeks</time_frame>
    <description>Elayza kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Sugar</measure>
    <time_frame>8 weeks</time_frame>
    <description>FBS (Fasting Blood Sugar) mmol/lit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>β- glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8.5 g/d of Oat Supplement Containing 3g β- glucan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8.5 g/d Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>β- glucan</intervention_name>
    <description>8.5 g/d of Oat Supplement Containing 3g β- glucan</description>
    <arm_group_label>β- glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>8.5 g/d Maltodextrin</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Non Alcoholic Fatty Liver Disease From Both Sex

          -  Age 18-55 years

          -  BMI more than 25 Kg/m2

        Exclusion Criteria:

          -  Alcohol Consumption

          -  Pregnancy or lactation or menopause

          -  Being a professional athlete

          -  A history of cancer

          -  Risk of high blood pressure (in the case of drug use)

          -  Heart disease - cardiovascular, pulmonary, renal and diabetes

          -  Liver transplantation and other chronic or acute Liver diseases such as hepatitis B, C
             and liver infections

          -  The History of inherited disorders affecting the liver

          -  A history of autoimmune disease

          -  History of food allergies

          -  Taking certain medications such as blood pressure control, statins, insulin
             sensitivity enhancers and hepatotoxic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Alizadeh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nutrition, School of Medicine, Urmia University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shekh-al- rais Clinic</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Navideh Youshari, MSc. Student</last_name>
      <email>navideh_youshari@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Mohammad Alizadeh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehrangiz Ebrahimi Mameghani, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Alcoholic Fatty Liver Disease(NAFLD)</keyword>
  <keyword>β- glucan</keyword>
  <keyword>Appetite</keyword>
  <keyword>Insulin Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

